Welcome to our dedicated page for Sintx Technologies SEC filings (Ticker: SINT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to SINTX Technologies, Inc. (NASDAQ: SINT) SEC filings, offering detailed insight into the company’s silicon nitride biomaterials business, capital structure, and governance. Filings are sourced in real time from the SEC’s EDGAR system and organized so investors can quickly locate key documents.
Through SINTX’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q, readers can review narrative business descriptions, risk factors, financial statements, and management’s discussion of its advanced ceramics and medical device operations. These reports also describe the company’s focus on infection‑resistant silicon nitride devices, polymer composites, and antipathogenic fabric technologies, as well as its U.S.‑based manufacturing footprint and patent portfolio.
Current reports on Form 8‑K document material events such as FDA 510(k) submissions and clearances, asset purchase agreements, at‑the‑market offering arrangements, warrant inducement transactions, and other financing activities. For example, recent 8‑K filings describe an ATM Offering Agreement with H.C. Wainwright & Co., an inducement agreement related to warrant exercises, and an asset purchase agreement for foot and ankle implant assets.
The DEF 14A proxy statement provides information on board elections, auditor ratification, executive compensation proposals, and equity incentive plans, along with details about the annual meeting of stockholders. Together, these filings help investors understand SINTX’s governance structure and shareholder matters.
Stock Titan’s platform enhances these documents with AI‑powered summaries that highlight important sections, such as business updates, capital‑raising terms, and key risk disclosures, reducing the time needed to interpret lengthy filings. Users can also review Form 4 and related insider transaction filings to see how directors and officers transact in SINTX common stock over time.
By using this page, investors can efficiently navigate SINTX’s 10‑K, 10‑Q, 8‑K, proxy, and insider filings, while AI‑generated insights point to the sections most relevant to the company’s silicon nitride technology platform and financial condition.
Kevin Patrick Murphy reports beneficial ownership of 225,914 shares of Sintx Technologies, Inc., representing 8.2% of the outstanding common stock based on an outstanding share count of 2,758,865. The disclosed position consists of 138,957 shares of common stock and 86,957 warrants to purchase common stock, and the filer reports sole voting and sole dispositive power over the full amount. The filing states the securities were not acquired to change or influence control of the issuer. The statement is filed on behalf of an individual reporting person, Kevin Patrick Murphy, who identifies as a U.S. citizen.
Jay M. Moyes, a director of SiNtx Technologies, Inc. (SINT), reported a purchase of 3,000 shares of common stock on 08/26/2025 at a reported price of $3.5854 per share. Following the transaction, he beneficially owns 3,000 shares directly. The Form 4 was signed under power of attorney on 08/27/2025. No derivative transactions or additional holdings were reported.
Gregg R. Honigblum, a Director and Chief Investment Officer of SiNtx Technologies, Inc. (SINT), reported multiple open-market purchases on 08/26/2025. The Form 4 shows ten separate purchases of 5,000 shares each, bringing his total beneficial ownership to 64,000 shares. Purchase prices ranged from $3.60 to $3.75 per share. The filing was signed by an agent on 08/27/2025.
Eric K. Olson, President and CEO and a director of Sintx Technologies, Inc. (SINT), reported four open-market purchases on 08/22/2025. The filings show acquisitions of 3,500 shares at $3.37, 5,000 shares at $3.69, 775 shares at $3.64, and 1,200 shares at $3.67, for a total of 10,475 shares purchased that day. Following these transactions, Mr. Olson beneficially owned 24,975 shares. The Form 4 was signed by an authorized representative on 08/25/2025.
On 22 Jul 2025, SINTX Technologies (SINT) filed a Form 8-K (Item 7.01) to furnish a press release announcing it has submitted a 510(k) application to the U.S. Food & Drug Administration for silicon-nitride foot & ankle medical devices. The disclosure is informational only and is not deemed “filed” for liability purposes. No financial statements, revenue guidance, or cost estimates accompany the submission. While the filing marks a key regulatory milestone that could enable U.S. commercialization, the company did not provide an expected review timeline, market size, or projected financial impact.
SINTX Technologies (NASDAQ:SINT) filed an 8-K announcing a definitive Asset Purchase Agreement signed 23 Jun 2025 with Sinaptic Surgical to acquire substantially all foot-and-ankle implant assets. Consideration is warrants for up to 325,000 SINT shares at $6.30, vesting on FDA 510(k) clearance and cumulative revenue milestones of $2.5-$15 million, and expiring after five years. Sinaptic will also purchase 216,450 shares at $3.465 in a private placement. Upon exceeding $15 million net revenue within four years, Sinaptic earns a 5 % royalty on related sales for two years. Closing is targeted for 1 Jul 2025, subject to customary conditions, and SINTX will file a resale registration within 90 days. The deal provides immediate capital, broadens SINTX’s product pipeline, and aligns future dilution with commercial success.
Director Mark Lewis Anderson of Sintx Technologies has reported a significant insider purchase of company shares. On June 18, 2025, Anderson acquired 10,000 shares of Common Stock at a price of $3.30 per share, representing a total investment of $33,000.
Following this transaction, Anderson's direct ownership increased to 15,000 shares of Sintx Technologies common stock. The purchase was executed as a standard market transaction and was reported through Form 4 filed with the SEC on June 28, 2025.
This insider buying activity by a board member could be viewed as a positive signal about the company's prospects, as directors often purchase shares when they believe the stock is undervalued or expect positive developments. The transaction was authorized through power of attorney by Kevin Ontiveros.